05 Feb PHOTON-2 Study Addresses Combination Hepatitis C Pill For HIV+ Patients
Medical Research: What is the background for this study? What are the main findings?
Prof. Molina: Treatment of co-infected patients is complicated by drug drug interactions with HIV drugs, and the news DAAs are not very potent on HCV G2 and 3 infections.
Medical Research: What should clinicians and patients take away from your report?
Prof. Molina: The simple combination of sofosbuvir plus ribavirin (available as a generic drug) provides potent response rates above 80% for co-infected patients with all genotypes, with limited drug drug interactions with HIV drugs.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Prof. Assess new combinations of DAAs, also with pangenotypic activity and limited drug drug interactions with HIV drugs, better tolerated and allowing shorter treatment duration.
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
Prof Jean-Michel Molina, MD Chloe Orkin, MDb,David M Iser, MBBSc,Francisco-Xavier Zamora, MDd,Mark Nelson, MBBSe,Prof Christoph Stephan, MDf,Benedetta Massetto, MDg, Anuj Gaggar, MDg,Liyun Ni, MAg,Evguenia Svarovskaia, PhDg,Diana Brainard, MDg, G Mani Subramanian, MDg,John G McHutchison, MDg,Prof Massimo Puoti, MDh, Prof Jürgen K Rockstroh, MDi, for the PHOTON-2 study team
MedicalResearch.com Interview with:, & Prof Jean-Michel Molina (2015). PHOTON-2 Study Addresses Combination Hepatitis C Pill For HIV+ Patients MedicalResearch.com